Veeva Systems Cl A saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
Veeva Systems Cl A is currently forming a consolidation, with a 258.93 buy point. See if the stock can break out in heavy trade at least 40% higher than normal.
The stock earns a 97 EPS Rating, which means its recent quarterly and annual earnings growth tops 97% of all stocks.
Its Accumulation/Distribution Rating of D- shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
The company reported a 26% rise in earnings for Q4. Sales growth increased 14%, up from 13% in the prior quarter. That marks one quarter of increasing revenue growth. The company's next quarterly report is expected on or around May. 28.
Veeva Systems Cl A holds the No. 4 rank among its peers in the Computer Software-Medical industry group. Doximity is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
